Showing 1041-1050 of 1614 results for "".
- Visus Therapeutics to Host Its First Capital Markets Day Tomorrowhttps://modernod.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Market Scope: Ophthalmic Laser Market Expected to Total $376.4 Million in 2021https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compound annual rate of 2.4 percent from 2021 to 2026, according to Market Scope estimates. Factor
- Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/Ocular Therapeutix has received notification from the FDA confirming it has fulfilled all post-approval study requirements for ReSure Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the
- Market Scope: Backlog of 6 Million Cataract Surgeries Will Help Drive IOL Market Through 2026https://modernod.com/news/backlog-of-6-million-cataract-surgeries-will-help-drive-iol-market-through-2026/2479127/Pandemic-impacted 2020 led to a backlog of more than 6 million cataract surgeries globally, as procedures declined 25 percent to 22 million, the lowest number since 2010, mainly due to COVID-related shutdowns in elective surgeries, according to a Market Scope report. The amount of time it
- Aerie Pharmaceuticals Receives Marketing Authorization of Roclanda in Great Britainhttps://modernod.com/news/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-in-great-britain/2479089/Aerie Pharmaceuticals announced that Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops solution (latanoprost + netarsudil) has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Roclanda is indicated for the reduction of el
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion by 2026https://modernod.com/news/steady-growth-new-technologies-will-drive-retinal-surgery-device-market-to-1-36-billion-by-2026/2479005/The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report. Retina surgery device sales are driven almost entirely by vitrectomy, a procedure which involves removal of the